スペラファーマ List of News Articles

Sperapharma Co., Ltd. will be exhibiting at the 26th "INTERPHEX JAPAN [Pharmaceuticals][Cosmetics] Manufacturing Exhibition" held at Tokyo Big Sight. This exhibition showcases technologies related to the manufacturing of pharmaceuticals and cosmetics all in one place. We will be jointly exhibiting with Iwaki Pharmaceutical Sakura Factory Co., Ltd., which shares the fine chemical business within the Astenaholdings Group. If you would like to have a meeting during the event, please feel free to contact us. Additionally, we will send an IPJ 2024 VIP invitation ticket to everyone who visits our booth or makes an appointment for a meeting. We sincerely look forward to seeing you all.

We will hold an online webinar as the 13th installment of our webinar series titled "Examples of Continuous Services from Active Pharmaceutical Ingredient Process Development to Manufacturing." In this webinar, we plan to focus on a continuous project from the development to the manufacturing process of clinical trial active pharmaceutical ingredients, showcasing five examples from the numerous service achievements we have provided to our clients. This webinar is recommended for those involved in pharmaceutical process development and those involved in selecting contract manufacturers for clinical trial active pharmaceutical ingredients. If you have any questions, please feel free to contact us.

At Spela Pharma Co., Ltd., we are adding cutting-edge MicroED to our lineup of conventional X-ray analysis, opening a new chapter in crystal structure analysis. With this product, our structural analysis can measure extremely small crystals that are difficult to analyze with single crystal X-ray structure analysis equipment, as well as crystalline powders and mixtures. The determination of complex structures becomes easier, accelerating catalyst design and reaction design, contributing to process chemistry. We are incorporating structural analysis using MicroED into our service lineup, providing stronger support for our customers' research and development from various aspects. For more details, please refer to the related links.

Spera Pharma Co., Ltd. was certified as a "Health Management Excellent Corporation 2024 (Small and Medium-sized Enterprises Division)" on March 11, 2024, under the health management certification system implemented by the Ministry of Economy, Trade and Industry and the Japan Health Conference. Based on our health management declaration, we will continue to be a company where employees can work brightly, energetically, and for a long time by implementing measures that utilize the framework of the health management excellent corporation certification system to maintain and promote employee health. Furthermore, we aim to link our efforts to maintain and promote employee health to the revitalization of the organization and the improvement of productivity, striving for business continuity and sustainable growth.

Our company, along with Axcelead Drug Discovery Partners, Junsei Chemical Co., Ltd., Toray Research Center, Inc., and Mediford, has launched the "Shonan Drug Discovery Support Consortium," based at the Shonan Health Innovation Park (Shonan I-Park). In the pharmaceutical industry, due to the diversification of modalities and the rising costs of drug development, outsourcing various processes in drug research and development to external providers such as CROs and CDMOs is progressing, and this is seen as an important form of open innovation. Additionally, many ventures and startups established to implement spin-outs from pharmaceutical companies or academia often possess only a portion of the necessary research functions, making it crucial to supplement lacking technologies and capabilities through outsourcing.

Sperapharma Co., Ltd. will hold the 12th installment of its webinar series titled "Fundamentals and Applications of MicroED Crystal Structure Analysis: Interesting Case Studies of Low Molecular Weight Drug Structure Analysis." In recent years, one of the advancements in analytical instruments has been the significant attention garnered by crystal structure analysis using MicroED with electron beams. Our company has achieved many successful analyses by using MicroED for compounds that were difficult to analyze with X-rays. In this webinar, we will present interesting case studies, including accurate polymorph discrimination, structural determination of natural products, and methods for determining absolute stereochemistry, as well as introduce the services offered by Sperapharma.

We will be exhibiting at "CPhI Japan 2024," which will be held at Tokyo Big Sight from April 17 to 19, 2024. This is a joint exhibition with Spiranexus Inc. and Iwaki Pharmaceutical Sakura Factory Co., Ltd., both of which are part of the Astena Holdings Group and share the fine chemical business. We sincerely look forward to your visit. 【Exhibitor Presentation】 ■ Date and Time: April 17 (Wed) 15:00-15:30 - Title: A New Era of Nanocrystal Structure Analysis Opened by MicroED ~Examples of Crystal Polymorph Discrimination and Structural Analysis~ ■ Date and Time: April 18 (Thu) 14:30-15:00 - Introduction of High Pharmacological Activity Active Pharmaceutical Ingredient Manufacturing Equipment and Proposal of Contract Synthesis Services 【Process Chemistry Seminar】 ■ Date and Time: April 18 (Thu) 13:00-13:45 - Challenges to Important Issues of Crystal Polymorphism in Process Chemistry ~Late-appearing Polymorph, Discrimination of Crystal Polymorphs~

Sperapharma Co., Ltd. will hold the 11th webinar titled "Special Lecture: Ecosystem Towards the Cure of Cancer." CAR-T therapy is beneficial for refractory or resistant blood cancers. We want to further evolve such cell therapies using advanced technologies and make them practical for early-stage cancer and prevention as well. To achieve this, an ecosystem is needed where more people can receive cell therapy at a relatively low cost. This time, we will specifically discuss this ecosystem.

Sperapharma Co., Ltd. will hold the 10th webinar in its series titled "Analysis of Lipid Nanoparticles (LNP) that have begun to attract attention as Nucleic Acid DDS and Quality Evaluation Methods for the Underlying Bio and Mid-sized Pharmaceuticals." This webinar is recommended for those involved in the development of bio and mid-sized pharmaceuticals and LNP formulations, as well as those interested in our contract services and initiatives. In this webinar, we will introduce an overview of the quality evaluation methods for LNP formulations based on the analytical techniques for bio pharmaceuticals and mid-sized pharmaceuticals, which serve as the foundation for the required quality evaluation technologies for LNP formulations, along with the services we provide. We sincerely look forward to your participation.